⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385765 | 1.00 | — | — | |
| SCHEMBL75987 | 1.00 | — | — | |
| SCHEMBL1399909 | 0.92 | — | — | |
| SCHEMBL323151 | 0.92 | — | — | |
| SCHEMBL4162100 | 0.92 | — | — | |
| SCHEMBL11877100 | 0.90 | — | — | |
| SCHEMBL2916620 | 0.79 | — | — | |
| SCHEMBL3165751 | 0.79 | — | — | |
| SCHEMBL2102547 | 0.79 | — | — | |
| SCHEMBL5118144 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-05-03 | — | — | US | claimed |
| EP-3256132-A1 | PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Merck Patent GmbH (DE) | 2017-12-20 | — | — | EP | claimed |
| WO-2016128140-A1 | PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | MERCK PATENT GMBH (DE) | 2016-08-18 | — | — | WO | claimed |
| EP-2493870-B1 | CHROMENONE DERIVATIVES WITH ANTI -TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2014-12-17 | — | — | EP | claimed |
| EP-2064192-B1 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY INC (US) | 2014-05-14 | — | — | EP | claimed |
| US-8399460-B2 | Chromenone derivatives | ASTRAZENECA AB (GB) | 2013-03-19 | — | — | US | claimed |
| US-8268868-B2 | 5-pyridinone substituted indazoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-09-18 | — | — | US | claimed |
| EP-2493870-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | AstraZeneca AB (SE) | 2012-09-05 | — | — | EP | claimed |
| US-8101632-B2 | 5-furopyridinone substituted indazoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-01-24 | — | — | US | claimed |
| WO-2011051704-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2011-05-05 | — | — | WO | claimed |
| US-6297269-B1 | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors | PFIZER INC. | 2001-10-02 | — | — | US | claimed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | claimed |
| WO-2001068055-A1 | PHARMACEUTICAL COMPOSITIONS OF GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2001-09-20 | — | — | WO | claimed |
| EP-0832066-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-09-12 | — | — | EP | claimed |
| EP-0978279-A1 | Inhibitors of human glycogen phosphorylase | Pfizer Products Inc. (US) | 2000-02-09 | — | — | EP | claimed |
| US-5952322-A | AMIDE-SUBSTITUTED BENZIMIDAZOLE, INDOLE DERIVATIVES | PFIZER INC. (US) | 1999-09-14 | — | — | US | claimed |
| EP-0846464-A2 | Use of glycogen phosphorylase inhibitor for reducing non-cardiac tissue damage resulting from ischemia | PFIZER INC. (US) | 1998-06-10 | — | — | EP | claimed |
| EP-0832066-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996039385-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1996-12-12 | — | — | WO | claimed |
| US-5079359-A | Ligand to metals with Lewis acidity, catalyst for assymetric synthesis | TOSOH CORPORATION (JP) | 1992-01-07 | — | — | US | claimed |